NEW YORK, NY / ACCESSWIRE / April 3, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Luckin Coffee Inc. (LK)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/luckin-coffee-inc-loss-submission-form?prid=5908&wire=1
Lead Plaintiff Deadline: April 13, 2020
Class Period: May 17, 2019 to April 2, 2020
Allegations against LK include that: (i) certain of Luckin's financial performance metrics, including per-store per-day sales, net selling price per item, advertising expenses, and revenue contribution from "other products" were inflated; (ii) Luckin's financial results thus overstated the Company's financial health and were consequently unreliable; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Tilray, Inc. (TLRY)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tilray-inc-loss-submission-form?prid=5908&wire=1
Lead Plaintiff Deadline: May 5, 2020
Class Period: January 15, 2019 to March 2, 2020
Allegations against TLRY include that: (i) the purported advantages of the marketing and revenue sharing agreement with Authentic Brands Group (the "ABG Agreement")were significantly overstated; (ii) the under performance of the ABG Agreement would foreseeably have a significant impact on the Company's financial results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
AnaptysBio, Inc. (ANAB)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/anaptysbio-inc-loss-submission-form?prid=5908&wire=1
Lead Plaintiff Deadline: May 26, 2020
Class Period: October 10, 2017 to November 7, 2019
Allegations against ANAB include that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: